Immuron (IMC) Stock Price, News & Analysis

Company Overview

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) to reduce the risk of contracting travelers' diarrhea in the United States, and Travelers' Diarrhea; and IMM-529, for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 175,856 shs
• Average Volume: N/A
• Market Capitalization: $17.75 million
• P/E Ratio: N/A
• Dividend Yield: 4.51%
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:IMC
• CIK: N/A
• Web: www.immuron.com.au
• Phone: 61 3 9824 5254
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A($0.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.94 million
• Net Margins: -141.49%
• Pretax Margin: N/A
• Return on Equity: -45.89%
• Return on Assets: -17.37%

Debt

• Debt-to-Equity Ratio: 1.37
• Current Ratio: 5.46
• Quick Ratio: 15.15

Sales & Book Value

• Annual Sales: $4.90 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 3.15
• Book Value: A$0.06 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 228,000,000
• Free Float: N/A
• Market Cap: $17.75 million
• Optionable: Not Optionable
• Beta: 1.10